IMPORTANCE Classic calciphylaxis associated with renal failure is a life-threatening disease. Warfarin-associated calciphylaxis without renal injury has been described, but whether it is a subset of classic calciphylaxis or a different entity remains unknown. We describe 1 case of warfarin-associated calciphylaxis, present data from 2 others from our institution, and review all cases of warfarin-associated calciphylaxis available in the literature. Our review indicates that warfarin-associated calciphylaxis is clinically and pathophysiologically distinct from classic calciphylaxis.
C alciphylaxis is a syndrome of cutaneous ischemic necrosis presenting as painful violaceous reticular patches or plaques that evolve into stellate ulcerations over the abdomen, thighs, and buttocks. 1, 2 These lesions result from arteriolar calcification with subsequent thrombosis, a 2-step process described by Weenig 2 as the cutaneous equivalent of a myocardial infarction. Calciphylaxis classically occurs with renal failure (calcific uremic arteriolopathy), but can also occur without kidney disease (nonuremic calciphylaxis), usually precipitated by hyperparathyroidism, liver disease, corticosteroids, malignant neoplasm, or warfarin. 1, 3, 4 We describe a case of warfarinassociated calciphylaxis, present data from 2 others from our institution, and review all cases of warfarin-associated calciphylaxis available in the literature. Our review indicates that warfarin-associated calciphylaxis is a distinct clinical subgroup with separate pathophysiologic characteristics and a favorable prognosis.
Report of a Case
A woman in her 60s with hypertension, hyperlipidemia, rheumatoid arthritis, diabetes, and atrial fibrillation presented with 1-year history of livedo reticularis and new palpable purpura over her bilateral lower extremities. She did not have renal disease or hyperparathyroidism, but she had taken warfarin for 2 years. A biopsy specimen showed calcification of small-to medium-size vessels within the subcutis, fat necrosis, and neovascularization. Ten days later, the patient developed tender stellate ulcers with purpuric borders, surrounding fixed livedo, and retiform purpura on her right leg including and extending beyond the biopsy site ( Figure 1 A second biopsy specimen showed calcification of smallto medium-size vessels within the subcutis and fat necrosis without neovascularization (Figure 2A) . A von Kossa stain revealed perieccrine calcium deposition ( Figure 2B ). Owing to the presence of calcium within vessels in the subcutis, subcutaneous fat necrosis, perieccrine calcium deposition, and lack of clinically significant neovascularization, along with progression of clinical morphologic characteristics into fixed purpura, a diagnosis of calciphylaxis was made.
Warfarin was identified as the precipitant because the patient did not have renal failure or other risk factors. Treatment with rivaroxaban, pentoxifylline, and sodium thiosulfate resulted in full recovery.
Review of the Literature
We searched MEDLINE and Ovid without language or date restrictions using the terms "calciphylaxis and warfarin," "nonuremic calciphylaxis," and "nonuremic calciphylaxis." We defined nonuremic calciphylaxis as a histopathologic diagnosis 
Key Points
Question Is warfarin-associated calciphylaxis a distinct disease when compared with classic calciphylaxis, and, if so, what are its features?
Findings In this review of reports of 18 patients with warfarin-associated calciphylaxis, 15 had used warfarin for an average of 32 months prior to calciphylaxis onset, and the most common treatments were substitution of heparin or low-molecular weight heparin for warfarin, intravenous sodium thiosulfate, and hyperbaric oxygen. Survival after hospital discharge was high with 15 cases (83%) reporting full recovery and 3 cases ending in death.
Meaning Warfarin-associated calciphylaxis is distinct from classic calciphylaxis in pathogenesis, course, and outcome.
of calciphylaxis without severe kidney disease (serum creatinine level >3 mg/dL, GFR<15 mL/min, acute kidney injury requiring dialysis, and renal transplantation). We found 15 cases of warfarin-associated nonuremic calciphylaxis in the literature and 3 cases from our institution. [5] [6] [7] [8] [9] Patients were predominantly female (15 of 18 [83%]). Lesions were usually below the knees (12 of 18, 67%) but also on thighs, abdomen, and breasts (6 of 18 [33%]). Duration of warfarin prior to calciphylaxis onset ranged from 1 to 168 months (mean, 32 months). No cases reported elevated calciumphosphate product, hypercoagulability, or rheumatologic disease ( Table 1 and Table 2 ).
Histopathologic analysis revealed calcification in all cases, most often in the tunica media (n = 8 [44%]) or in the vessel lumen and tunica intima (n = 7 [39%]). Other findings included ischemia and/or necrosis (n = 10 [56%]), extravascular calcification (n = 7 [39%]), endovascular fibrosis and/or hyperplasia (n = 6 [33%]), and thrombosis (n = 5 [28%]). Multiple biopsy specimens were required in 8 cases (44%) to render a definitive diagnosis.
Treatments included heparin (n = 13 patients [72%]), sodium thiosulfate (n = 9 [50%]), and hyperbaric oxygen (n = 3 patients [17%]). Three cases did not report either continuing or discontinuing warfarin; every other case reported stopping warfarin therapy. Survival to discharge was high (n = 15 patients [83%]). We did not observe recurrence after cessation of warfarin.
Discussion
Calciphylaxis was the most probable diagnosis in the case described herein because of the combination of specific histopathologic features, consistent morphologic characteristics, and exclusion of other disease (vasculitis, thrombophilia, and infection). The most compelling histopathologic evidence for calciphylaxis is a combination of vascular calcification of smallto medium-size vessels with fat necrosis and proximal vascular thrombosis. Distinguishing calciphylaxis from atherosclerotic disease with secondary vascular calcification and necrosis is challenging. Thrombosis is absent in atherosclerosis, but may also be missed in calciphylaxis owing to sampling error. A von Kossa stain may reveal perieccrine calcification, which can support the diagnosis of calciphyalxis. 20 Perieccrine calcification was present in this case, strongly supporting the diagnosis of calciphylaxis in the context of stellate ulceration and exclusion of other disease.
In this series, warfarin-associated calciphylaxis often occurred in the presence of other risk factors for vessel narrowing or thrombosis, but these factors were not sufficient to cause disease. In our case series, warfarin was the proximal inciting risk factor for calciphylaxis, and symptoms resolved after discontinuation of warfarin. Although warfarin is an anticoagulant, it increases the odds of calciphylaxis up to 10-fold. 1, 3, 21 The pathogenesis of warfarin-associated calciphylaxis is incompletely understood, but distinct from both classic calciphylaxis and warfarin-induced necrosis. Evidence suggests that warfarin promotes vascular calcification by inhibiting vitamin K-dependent matrix Gla protein, a protein that prevents calcium deposition in arteries. 22 Thrombosis, the second step necessary for calciphylaxis, is counterintuitively increased by warfarin. We suspect that warfarin incites thrombosis by acting on vascular endothelial cells, which regulate the local microenvironment of procoagulant and anticoagulant factors by secreting proteins C and S in response to stress. 23 Warfarin decreases protein S secretion in cultured endothelial cells by more than 90%. 24 Thus, warfarin may inhibit normal endothelial cell responses to calcification and stress by blocking protein C and S, tipping the local balance in favor of thrombosis. This is distinct from systemic protein C and S deficiency, which typically occurs within 2 weeks and causes venous, not arterial, thrombosis. Clinically, warfarin-associated calciphylaxis and classic calciphylaxis both present with indurated plaques with overlying retiform purpura and central necrosis. However, this study identifies key differences between the 2 diseases. Warfarin-associated calciphylaxis tends to ulcerate below the knee, while ulcerations of classic calciphylaxis are usually proximal and over fat-bearing regions. 1, 4 Most important, mortality for warfarin-associated calciphylaxis in this study is 17%, much lower than the 50% to 80% mortality of classic calciphylaxis. 1, 4 This difference may be confounded by absence of renal failure in our population and the distal location of ulcers. Warfarin-induced skin necrosis differs from warfarinassociated calciphylaxis in clinical presentation and pathogenesis. Warfarin-induced skin necrosis presents with hemorrhagic bullae with surrounding retiform purpura 3 to 10 Research Brief Report Warfarin-Associated Nonuremic Calciphylaxis days after warfarin initiation, whereas warfarin-associated calciphylaxis presented on average after 32 months as indurated retiform purpuric plaques with central necrosis favoring the lower extremities. Warfarin-induced skin necrosis arises from immediate hypercoagulability from decreased systemic protein C and S, whereas warfarin-associated calciphylaxis probably involves chronic vascular calcification and local inhibition of protein C and S with normal systemic levels. These distinctions inform clinical management of warfarin-associated calciphylaxis. Clinicians should be alert to necrotic skin lesions well past the 10-day interval typical of warfarin-induced skin necrosis. Warfarin should be stopped, but protein C replacement is not beneficial because there is no systemic deficiency in protein C. Thrombolytics or anticoagulants can be used to reestablish perfusion. Sodium thiosulfate and/or bisphosphonates seem to benefit patients with nonuremic calciphylaxis, arguing that these therapies do more than alter the calciumphosphate product. 25 Sodium thiosulfate, for example, has antioxidant properties that aid wound healing. 25 Vitamin K supplementation could theoretically counteract warfarin induced arteriolar c alcific ation. The VitaVasK trial (NCT01742273), an evaluation of vitamin K for reducing vascular calcification, may provide evidence for vitamin K treatment in calciphylaxis.
Conclusions
Patients with warfarin-associated calciphylaxis are a distinct subgroup of patients with calciphylaxis. In particular, patients with warfarin-associated calciphylaxis have no calcium imbalance and have a favorable prognosis compared with those with classic calciphylaxis. Warfarin may cause both calcification of arteries and paradoxical thrombosis through local action on vascular endothelium. Better understanding the pathogenesis of calciphylaxis may lead to more specific and effective therapies. 
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